U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07170254) titled 'A Clinical Study on the Evaluation of BD114 for the Treatment HPV-16-Related Cervical HSIL' on Sept. 05.
Brief Summary: This study is intented to evaluate the safety, and tolerability and preliminary efficacy of Instantaneous CRISPR/Cas9 Gene Editing Therapy (BD114 virus-like particle, also BD114) for the treatment of high-grade squamous intraepithelial lesions (HSIL) associated with HPV-16 infection.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
High-grade Squamous Intraepithelial Lesions (HSIL)
Intervention:
GENETIC: BD114VLP, or BD114
CRISPR/Cas9 instantaneous gene editing therapy, called BD114VLP (a...